Genetics of Pancreatic Cancer

Matt Yurgelun, MD
Dana-Farber Cancer Institute
Gastrointestinal Cancer Center
Cancer Genetics & Prevention Program

Pancreatic Cancer Action Network
Educational Seminar
March 28, 2014

Disclosures

• No relevant disclosures or conflicts of interest to report
Objectives

• Review basic concepts of genetics and how they apply to understanding pancreatic cancer risks

• Discuss current understanding of hereditary/genetic syndromes associated with pancreatic cancer risk

• Discuss current understanding of “familial pancreatic cancer,” (families with “too much” pancreatic cancer)

• Review the evolving data on strategies to screen for pancreatic cancer in high-risk individuals

Some families have inherited risks of pancreatic cancer

15 first-degree relatives of a pancreatic cancer patient

How can we understand and reduce this family's risk of pancreatic cancer?
Understanding and reducing risk

• **Identifying** high-risk individuals
  – When to consider a genetic predisposition to pancreatic cancer?
  – Families with “too much” pancreatic cancer

• **Managing** high-risk individuals
  – Can we effectively screen for pancreatic cancer?
  – Other risk-reducing interventions?

Outline

• Primer on Genetics

• Inherited Risks of Pancreatic Cancer
  – Specific Genetic Syndromes
  – “Familial Pancreatic Cancer”

• Pancreatic Cancer Screening
  – Who?
  – When?
  – How?
Outline

• Primer on Genetics

• Inherited Risks of Pancreatic Cancer
  – Specific Genetic Syndromes
  – “Familial Pancreatic Cancer”

• Pancreatic Cancer Screening
  – Who?
  – When?
  – How?
Cancer is a Genetic Disease

Normal cells and cancer cells contain the same 30,000 genes.
- What distinguishes them is which genes are turned on and off

Chromosomes, DNA, and Genes

Adapted from Understanding Gene Testing, NIH, 1995
The DNA Double Helix

Bases

Sugar phosphate backbone

Base pair

Adenine (A)  Cytosine (C)  Thymine (T)  Guanine (G)

Disease-Associated Mutations
Alter Protein Function

Functional protein

Nonfunctional or missing protein
Genetic Code

A **codon** is made of 3 base pairs

- 64 codons total

1 codon (AUG) encodes methionine *and* starts translation of all proteins

- 61 codons encode 20 amino acids (redundant code)

- 3 codons stop protein translation

---

Examples of Mutation Types

**Wild Type (no mutation):** The red dog saw the fox and the cat run.

- **Small Insertion:** The red do**X** gsa wth efo xan dth eca tru n.
- **Large Insertion:** The red dog **and the big bat** saw the fox and the cat run.
- **Small Deletion:** The red dog sat hefox and the cat run.
- **Large Deletion:** The red dog sat hefox and the cat run.
- **Rearrangement:** The red **__** fox and the cat run dog saw the.
- **Duplication:** The red dog saw the fox and The red dog the cat run.
- **Missense:** The red dog saw the f**Ax** and the cat run.
- **Variant:** The red dog saw the fox and the K**at** run.
Some key terms

- **Genotype**
  - The genetic makeup of a cell or individual

- **Germline mutation**
  - A mutation in the patient
  - A mutation in cells that can be passed on to offspring
    - Sperm
    - Oocyte
  - Usually inherited from a parent
  - Present in every cell in the body

- **Phenotype**
  - The observed traits of a cell or individual

- **Somatic mutation**
  - A mutation in the tumor
  - Mutations that develop in differentiated/mature cells
  - Not inherited
  - Cannot be passed on to children
  - Only present in cells that acquire the mutation
  - Potential for “targeted” therapies against a specific mutation
    - Ability to spare non-cancerous cells

Knudson Two-Hit Hypothesis

In patients who inherit a germline mutation, the “first hit” is already present in every cell in their body

Slide courtesy of Dr. Judy Garber
Autosomal Dominant Inheritance

- Each child has 50% chance of inheriting the mutation
- No “skipped generations”
- Equally transmitted by men and women

Concept of Penetrance

- Inheriting a cancer susceptibility gene does not guarantee the development of cancer

- Reasons for incomplete penetrance?
  - Environmental effects?
  - Other “modifier” genes?
Why do genetic testing for inherited cancer syndromes?

• Identify other cancers for which the patient may be at risk

• Offer predictive testing to other family members to see who might also be at risk for cancer in the future

Why test someone who’s “affected”?

Helps guide interpretation of “negative” or “variant” test results

A “negative” genetic test result in an unaffected patient is considered uninformative—it could be that they did not inherit a mutation carried by other family members OR it could be that there is no mutation that can be detected.
Once the mutation is found in one person in the family, the rest of the family can be tested to see whether they do or do NOT share the mutation.

Such “single site” testing is considered truly informative – you either have it or you don’t (also cheaper and quicker).

Outline

• Primer on Genetics

• Inherited Risks of Pancreatic Cancer
  – Specific Genetic Syndromes
  – “Familial Pancreatic Cancer”

• Pancreatic Cancer Screening
  – Who?
  – When?
  – How?
Hereditary Cancer: Identifying who is at risk?

- Breast cancer
  - 10-20% of “triple-negative” breast cancer due to BRCA1 or BRCA2 mutations
  - >10% of breast cancers in women of Ashkenazi Jewish descent due to BRCA1/2 mutations

- Ovarian/Fallopian Tube/Peritoneal cancer
  - 5-15% due to BRCA1 or BRCA2 mutations
  - 30-40% of ovarian cancers in women of Ashkenazi Jewish descent due to BRCA1/2 mutations

- Colorectal cancer
  - 3% due to Lynch syndrome (HNPCC)
  - 1% due to familial polyposis syndromes

- Uterine (endometrial) cancer
  - 2% due to Lynch syndrome (HNPCC)

- Pancreatic cancer
  - ??

Hereditary Cancer: How to manage and reduce risk?

- Breast cancer
  - Early-onset breast screening: mammography, ultrasound, MRI
  - Risk-reducing prophylactic mastectomy

- Ovarian/Fallopian Tube/Peritoneal cancer
  - Screening is likely ineffective
  - Risk-reducing prophylactic salpingo-oophorectomy at the completion of childbirth

- Colorectal cancer
  - Annual colonoscopies
  - Consideration of risk-reducing prophylactic colectomy for some patients

- Uterine (endometrial) cancer
  - Risk-reducing prophylactic hysterectomy at the completion of childbirth

- Pancreatic cancer
  - ??
Defining Inherited Risks of Pancreatic Cancer

Hereditary Pancreatic Cancer Risk

• Having a known genetic syndrome/mutation that increased pancreatic cancer risk

• Other associated cancer risks, depending on specific syndrome/mutation

Familial Pancreatic Cancer (FPC)

• A term used to describe families with “too much” pancreatic cancer
  — WITHOUT an identifiable genetic syndrome/mutation

Hereditary Susceptibility to Pancreatic Cancer

• Up to 10% of all pancreatic cancers occur in patients with a family history of pancreatic cancer

• Having a first degree relative with pancreatic cancer increases risk of disease
Defining Inherited Risks of Pancreatic Cancer

Hereditary Pancreatic Cancer Risk

- Having a known genetic syndrome/mutation that increased pancreatic cancer risk
- Other associated cancer risks, depending on specific syndrome/mutation

Familial Pancreatic Cancer (FPC)

- A term used to describe families with “too much” pancreatic cancer
  - WITHOUT an identifiable genetic syndrome/mutation

Identifiable Genetic Syndromes with Increased Pancreatic Cancer Risk

Not so rare...

- Hereditary breast/ovarian cancer (HBOC)
  - BRCA1 and BRCA2 genes
- Lynch syndrome (hereditary nonpolyposis colorectal cancer; HNPCC)
  - DNA mismatch repair genes: MLH1, MSH2, MSH6, PMS2, and EPCAM
- Other gene(s)?
  - ATM

Rare

- Peutz-Jeghers syndrome (PJS)
  - STX11
- Li-Fraumeni syndrome (LFS)
  - TP53 gene
- Familial multiple mole melanoma (FAMMM) syndrome
  - CDKN2A (p16) gene
- Hereditary pancreatitis
  - PRSS1 (cationic trypsinogen) gene
- Other gene(s)?
  - PALB2
BRCA1 and BRCA2

- Most common hereditary breast and ovarian cancer syndrome
  - ~60% lifetime risk of female breast cancer
  - ~20-40% lifetime risk of ovarian cancer

  *Overall risks of cancer in males are much lower, so family histories can be subtle*

- Roughly 2.5% of population with Ashkenazi Jewish heritage have BRCA1/2 mutations

- Thought to be most common identifiable genes underlying pancreatic cancer risk
  - Not early-onset pancreatic cancer
    - *Can be very difficult to get insurance coverage for BRCA1/2 testing in pancreatic cancer patients who are older and/or men*
Lynch syndrome (HNPCC)

• Most common hereditary GI cancer syndrome
  – 3% of all colorectal cancers
    • 20-80% lifetime risk of colorectal cancer
  – 2% of all uterine cancers
    • 20-60% lifetime risk of uterine cancer

• Typically, young onset cancers
  – Median age of diagnosis ~45

Aldred Scott Warthin, M.D., Ph.D.

• University of Michigan pathologist, 1895

  “His seamstress was depressed because she was convinced, based on her family history, that she would one day die of cancer of the female organs or bowels… [She] told Warthin that it was inevitable that she would die early in life because ‘Everyone in my family dies of those cancers.’”

  ➔ She later died at age 55 (1901) of metastatic endometrial cancer

  ➔ Warthin published a description of this “Family G” in 1913.

Lynch Syndrome Cancer Spectrum

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Lifetime Risk</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal cancer</td>
<td>28-75%</td>
<td>Risk may be lower in MSH6 and PMS2 mutation carriers.</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>27-60%</td>
<td>Usually endometrioid histology</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>6-20%</td>
<td>Usually endometrioid histology</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>&lt;1-6%</td>
<td>May be more common in Asian patients and those with MLH1 mutations</td>
</tr>
<tr>
<td>Urothelial cancers</td>
<td>8-12%</td>
<td>More common in MSH2 mutation carriers</td>
</tr>
<tr>
<td>Sebaceous neoplasms and</td>
<td>Varies,</td>
<td><em>Muir-Torre</em> variant; usually only seen in MLH1 or MSH2 mutation</td>
</tr>
<tr>
<td>keratoacanthomas</td>
<td>depending on family</td>
<td>mutation carriers</td>
</tr>
<tr>
<td>Small bowel carcinomas</td>
<td>~4%</td>
<td></td>
</tr>
<tr>
<td>Pancreatic cancer (exocrine)</td>
<td>3-4%</td>
<td></td>
</tr>
<tr>
<td>Biliary carcinomas</td>
<td>&lt;1-4%</td>
<td></td>
</tr>
<tr>
<td>CNS tumors</td>
<td>&lt;1-2%</td>
<td>&quot;Turcot&quot; variant; mostly gliomas</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>?</td>
<td></td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>?</td>
<td></td>
</tr>
</tbody>
</table>

Bonadona V, et al. JAMA 2011;305:2304-10
Goodenberger M and L. Leder; J Clin Gastroenterol 2011;45:488-492
Stoffel E, et al. Gastroenterology 2006;137:1621-1627

Risk of Pancreatic Cancer in Families With Lynch Syndrome

Fay Kastrinos, MD, MPH, Bhramar Mukherjee, PhD, Nabibah Tayob, MS, Fei Wang, MS, Jennifer Sparr, MD, Victoria M. Raymond, MD, Prathap Bandipalli, MD, Elena M. Stoffel, MD, MPH, Stephen B. Glabois, MD, MPH, Sapna Syngal, MD, MPH

<table>
<thead>
<tr>
<th>Age</th>
<th>Cumulative Risk Population (%)</th>
<th>Cumulative Risk Lynch Carriers % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>30</td>
<td>0.00</td>
<td>0.04</td>
</tr>
<tr>
<td>40</td>
<td>0.01</td>
<td>0.26</td>
</tr>
<tr>
<td>50</td>
<td>0.04</td>
<td>1.46 (0.56, 3.22)</td>
</tr>
<tr>
<td>60</td>
<td>0.18</td>
<td>2.16</td>
</tr>
<tr>
<td>70</td>
<td>0.52</td>
<td>3.95 (1.52, 6.63)</td>
</tr>
</tbody>
</table>

*Surveillance Epidemiology and End Results 2001-2005
Other Cancer Risks for Families With Lynch Syndrome

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Observed No.</th>
<th>Expected No.</th>
<th>SIR*</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Carriers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon cancer</td>
<td>16</td>
<td>0.78</td>
<td>20.48</td>
<td>11.71 to 33.27</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>6</td>
<td>0.20</td>
<td>30.62</td>
<td>11.24 to 66.64</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Ovary cancer</td>
<td>3</td>
<td>0.16</td>
<td>18.81</td>
<td>3.88 to 54.95</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Renal cancer</td>
<td>3</td>
<td>0.27</td>
<td>11.22</td>
<td>2.31 to 32.79</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Pancreas cancer</td>
<td>2</td>
<td>0.19</td>
<td>10.68</td>
<td>2.68 to 47.70</td>
<td>.001</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>2</td>
<td>0.20</td>
<td>9.78</td>
<td>1.18 to 35.30</td>
<td>.009</td>
</tr>
<tr>
<td>Urinary bladder cancer</td>
<td>2</td>
<td>0.21</td>
<td>9.51</td>
<td>1.15 to 34.37</td>
<td>.009</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>7</td>
<td>1.77</td>
<td>3.95</td>
<td>1.59 to 8.13</td>
<td>.001</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>3</td>
<td>1.21</td>
<td>2.49</td>
<td>0.51 to 7.27</td>
<td>.18</td>
</tr>
<tr>
<td>Noncarriers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon cancer</td>
<td>5</td>
<td>4.88</td>
<td>1.02</td>
<td>0.33 to 2.39</td>
<td>.97</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>3</td>
<td>4.68</td>
<td>0.64</td>
<td>0.13 to 1.87</td>
<td>.51</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>5</td>
<td>6.95</td>
<td>0.72</td>
<td>0.23 to 1.68</td>
<td>.52</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>9</td>
<td>5.53</td>
<td>1.63</td>
<td>0.74 to 3.09</td>
<td>.18</td>
</tr>
</tbody>
</table>

*Age-, Sex-, and Country-Specific SIRs for Carriers & Noncarriers Compared With the General Population


Rare syndromes

- **Peutz-Jeghers syndrome (PJS) – STK11 gene**
  - Lip freckling and small intestine polyps early in life
  - Breast cancer, colon cancer risks
  - Markedly elevated pancreatic cancer risk

- **Li-Fraumeni syndrome (LFS) – TP53 gene**
  - Risk of multiple lifetime cancers (>90% lifetime risk of any cancer)
    - Early breast cancer, sarcomas, leukemias/lymphomas, adrenal cancers
    - Gastric, colorectal, lung cancers
  - Association with pancreatic cancer, but frequency unclear

- **Familial multiple mole/melanoma (FAMMM) syndrome – CDKN2A (p16) gene**
  - Most commonly, atypical moles and melanomas are the predominant finding
  - Increased risk of pancreatic cancer; frequency unclear

- **Hereditary pancreatitis – PRSS1 gene**
  - Early-onset recurrent pancreatitis
  - Elevated pancreatic cancer risk (? Related to risk of pancreatitis)
Known Genetic Syndromes Associated with Increased Pancreatic Cancer Risk

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Culprit gene(s)</th>
<th>Pancreatic cancer risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary breast cancer</td>
<td>Fanconi anemia pathway genes (BRCA1, BRCA2, PALB2)</td>
<td>Up to 6-fold increased risk</td>
</tr>
<tr>
<td>Lynch syndrome</td>
<td>DNA mismatch repair genes (MLH1, MSH2, MSH6, PM2, EPCAM)</td>
<td>8-10-fold increased lifetime risk</td>
</tr>
<tr>
<td>Peutz-Jeghers syndrome</td>
<td>STK11</td>
<td>Up to 13-fold increased risk</td>
</tr>
<tr>
<td>Hereditary pancreatitis</td>
<td>PRSS1 (cational trypsinogen gene)</td>
<td>Up to 60-fold increased risk</td>
</tr>
<tr>
<td>Familial multiple mole and melanoma (FAMMM) syndrome</td>
<td>CDKN2A/p16</td>
<td>Up to 13-fold increased lifetime risk</td>
</tr>
<tr>
<td>Li-Fraumeni syndrome</td>
<td>TPS3</td>
<td>??</td>
</tr>
<tr>
<td>Ataxia-telangiectasia</td>
<td>ATM</td>
<td>??</td>
</tr>
</tbody>
</table>

When to do genetic testing?

- Minimal guidelines to help with this
  - Guidelines for BRCA1/2 testing, Lynch testing, etc, mention pancreatic cancer risks, but pancreatic cancer is far from the focus of these guidelines

- Insurance often doesn’t cover genetic testing for patients with pancreatic cancer, if they don’t meet other criteria
Defining Inherited Risks of Pancreatic Cancer

**Hereditary Pancreatic Cancer Risk**
- Having a known genetic syndrome/mutation that increased pancreatic cancer risk
- Other associated cancer risks, depending on specific syndrome/mutation

**Familial Pancreatic Cancer (FPC)**
- A term used to describe families with “too much” pancreatic cancer
  - WITHOUT an identifiable genetic syndrome/mutation

**Familial Pancreatic Cancer (FPC)**
- A term used to describe families (not individuals)
- Families with at least a pair of first-degree relatives (FDRs) with pancreatic cancer
Familial pancreatic cancer (FPC)

Families with at least a pair of first-degree relatives (FDRs) with pancreatic cancer

<table>
<thead>
<tr>
<th>≥3 FDRs with pancreatic cancer</th>
<th>Standard incidence ratio (95% CI)</th>
<th>Lifetime risk</th>
<th>Incidence per 100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>32 (10.4-74.7)</td>
<td>~40%</td>
<td>288</td>
<td></td>
</tr>
<tr>
<td>2 FDRs with pancreatic cancer</td>
<td>6.4 (1.8-16.4)</td>
<td>8-12%</td>
<td>58</td>
</tr>
<tr>
<td>1 FDR with pancreatic cancer</td>
<td>4.5 (0.54-16.3)</td>
<td>6.0%</td>
<td>41</td>
</tr>
<tr>
<td>General population</td>
<td>1 (1.3%)</td>
<td>9</td>
<td></td>
</tr>
</tbody>
</table>

Median age of pancreatic cancer diagnoses within FPC families is ~65 years old

Adapted from:
Outline

• Primer on Genetics

• Inherited Risks of Pancreatic Cancer
  – Specific Genetic Syndromes
  – “Familial Pancreatic Cancer”

• Pancreatic Cancer Screening
  – Who?
  – When?
  – How?
Reasons to Screen High Risk Individuals

• Surgical options exist for early pancreatic neoplasia

• Currently, >80% of pancreatic cancer diagnosed at advanced stages

• We know how to identify (at least some) individuals at high risk of pancreatic cancer

Reasons Not to Screen

• Currently, *no data on survival benefit* from screening and treatment of asymptomatic high-risk individuals

• Low sensitivity of some screening modalities

• False positives may lead to unnecessary surgery/biopsies

• High incidence of chronic pancreatitis changes in high-risk individuals

• Quality of life in patients undergoing screening

• Cost-effectiveness of different screening strategies remains to be determined
Pancreatic Cancer Screening

- Does it work?
- Who to screen?
- When to screen?
- How to screen?
- Potential downsides to screening?

2013 CAPS Consortium Statements – Key questions:

- Who should be screened for pancreatic cancer?
- How should pancreatic cancer screening and follow up be done?
- When should pancreatic surgery be considered?
- What are the goals of screening? What outcome(s) should be considered a success?
CAPS Consortium: Who should be screened?

- >5% lifetime risk, based on family history (FPC)
  - 3 or more family members with pancreatic cancer, if 1 is a first-degree relative
  - 2 or more first-degree relatives with pancreatic cancer

- >5% lifetime risk, based on genetic status
  - All patients with Peutz-Jeghers syndrome
  - BRCA, FAMMM, Lynch syndrome or PALB2 mutation carriers with 1 first-degree relative with pancreatic cancer
  - BRCA mutation carriers with 2 non-first-degree relatives with pancreatic cancer

Pancreatic Cancer – How to Screen?

- CT scans?
- MRI/MRCP?
- Endoscopic ultrasound (EUS)?
Imaging Can Detect Pancreatic Cancer/Precursor Lesions: *CT Scan*

**Advantages**
- Low cost
- Wide availability
- Standard procedures
- Can detect large lesions

**Disadvantages**
- Limited sensitivity, esp for smaller lesions
- Radiation exposure
- Allergic reactions and kidney damage from IV contrast

---

Imaging Can Detect Pancreatic Cancer/Precursor Lesions: *MRI/MRCP*

**Advantages:**
- High diagnostic accuracy (80-100% for main and side branch IPMN)
- No radiation
- Not operator dependant

**Disadvantages:**
- High cost
- Cannot accurately detect PanIN (pre-invasive) lesions in side branches
- Contraindicated in patients with metallic implants
- Claustrophobia
Imaging Can Detect Pancreatic Cancer/Precursor Lesions: **EUS**

**Advantages**
- No exposure to radiation
- Provides high-resolution images
- High diagnostic accuracy for cystic lesions (90%)
- Better visualization of parenchymal abnormalities

**Disadvantages**
- High cost
- Not widely available
- High inter-observer variability
- Risk associated with sedation and endoscopy

Pancreatic Cancer Screening

- 216 “high-risk” patients
  - 195 with FPC
  - 21 with *BRCA2* mutations and a family history of pancreatic cancer

- Screening with CT, MRCP, and EUS
  - CT scanning had much lower sensitivity than MRCP and EUS

Pancreatic Cancer Screening

• 42% of patients (92/216) had focal pancreatic lesion
  – Most commonly cysts (IPMNs)
    • 60% of patients with cysts had multiple cysts

• Incidence of abnormalities increased with age
  – 14% of subjects age <50
  – 53% of subjects age 60-69

• 5 patients went on to surgical resection of part/all of the pancreas
  – All had evidence of pre-invasive neoplasia
  – No invasive adenocarcinomas


CAPS Consortium:
How to screen? When to operate?

• Initial screening with MRI/MRCP and/or endoscopic ultrasound (EUS)

• Surgical consideration for “high-risk” lesions
  – Definition of “high-risk” is unclear

**Downsides to screening?**

- Very different scenario than other types of cancer screening/surveillance
  - Removing a colon polyp is not the same as pancreatic resection
  - Patients are anxious – no need to convince to get screened
  - Challenge will be not to over-screen
  - High rate of non-malignant lesions
  - Major risks: unnecessary intervention, anxiety

---

**Pancreatic Cancer Screening**

- **Does it work?**
  - Not yet proven….. we hope it works!
  - IF screening works, it is most likely to be effective in high-risk individuals

- **Who to screen?**
  - >5% lifetime risk based on family history and/or genetic status
    - Within FPC families, anyone who is a first-degree relative of someone with pancreatic cancer
    - Mutation carriers (*BRCA1/2*, Lynch, other syndromes) with pancreatic cancer in family
    - All patients with Peutz-Jeghers syndrome and hereditary pancreatitis (both rare)

- **When to screen?**
  - Age ≥50 (or 10 years younger than youngest diagnosis in family)
  - Age 30-35 in Peutz-Jeghers syndrome

- **How to screen?**
  - Annual screening, alternating MRI and endoscopic ultrasound (EUS)
  - Increased surveillance and aggressive management of IPMNs and other suspected lesions
  - At specialized centers (ideally under research protocols)

- **Potential downsides to screening?**
  - Anxiety related to pancreatic abnormalities/cysts
  - Additional testing procedures for cysts or incidental findings
WHO in this family should we be screening pancreatic cancer?

Summary

• Pancreatic cancer is often a familial/genetic disease
  – Most families with “too much” pancreatic cancer (FPC) will not have an identifiable genetic syndrome

• Identification of specific genetic syndromes requires ability to recognize family history patterns (and convincing insurance companies to pay for testing)
  – BRCA1/2
  – Lynch syndrome

• Pancreatic cancer screening should be considered for high-risk individuals
  – Need to emphasize limitations/risks, and the absence of data about the effectiveness of screening

• A deeper understanding of these issues is needed to get us to the point of being able to effectively prevent pancreatic cancer
Questions?

Matthew_Yurgelun@DFCI.Harvard.edu